Author(s)

Karla Andrea

Affiliation(s)

Digital Medicine Society (DiMe), Boston, MA, USA.

Corresponding Author

Karla Andrea

ABSTRACT

MicroRNA (miR) is involved in carcinogenesis and the development of human cancers. A large number of studies have been conducted on the expression of miR-186 in various cancers, including genitourinary system tumors. The results show that miR-186 affects various aspects of tumors. This biological process can be used as a marker for the diagnosis and prognosis assessment of genitourinary system tumors. This article reviews the research progress of miR-186 in urogenital tumors.

KEYWORDS

Genitourinary system tumors; MICRORNA-186; Tumor biology

CITE THIS PAPER

Karla Andrea. The role of microRNA-186 in urogenital tumors. World Journal of Clinical Sciences. 2024, 2(1): 4-7. DOI: 10.61784/wjcs240154.

REFERENCES

[1] Oliveto S, Mancino M, Manfrini N. Role of microRNAs in translation regulation and cancer. World J Biol Chem, 2017, 8(1): 45-56. DOI: 10.4331/wjbc.v8.i1.45.

[2] Jiao D, Wu M, Ji L. MicroRNA-186 suppresses cell prolif- eration and metastasis through targeting sentrin-specific protease 1 in renal cell carcinoma. Oncol Res, 2018, 26 (2): 249-259. DOI: 10.3727/096504017X14953948675430.

[3] Dong S, Wang R, Wang H. HOXD-AS1 promotes the epithelial to mesenchymal transition of ovarian cancer cells by regu- lating miR-186-5p and PIK3R3. J Exp Clin Cancer Res, 2019, 38(1): 110.DOI: 10.1186/s13046-019-1103-5.

[4] Zhang JJ, Wang DD, Du CX. Long noncoding RNA ANRIL promotes cervical cancer development by acting as a sponge of miR-186. Oncol Res, 2018, 26 (3): 345-352. DOI: 10.3727/096504017X14953948675449.

[5] Liu C, Wang J, Hu Y. Upregulation of kazrin F by miR-186 suppresses apoptosis but promotes epithelial-mesenchymal transition to contribute to malignancy in human cervical cancer cells. Chin J Cancer Res, 2017, 29(1): 45-56. DOI: 10.21147/j.issn.1000-9604.2017.01.06.

[6] Myatt SS, Wang J, Monteiro LJ. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res, 2010, 70 (1): 367-377. DOI: 10.1158/0008-5472. CAN-09-1891.

[7] He X, Ping J, Wen D. MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C. Exp Ther Med, 2017, 14(4): 3253-3258. DOI: 10.3892/etm. 2017. 4908.

[8] Yao K, He L, Gan Y. MiR-186 suppresses the growth and metastasis of bladder cancer by targeting NSBP1. Diagn Pathol, 2015(10): 146. DOI: 10.1186/s13000-015-0372-3.

[9] Li XD, Zhang JX, Jiang LJ. Overexpression of maelstrom promotes bladder urothelial carcinoma cell aggressiveness by epige- netically downregulating MTSS1 through DNMT3B. Oncogene, 2016, 35(49): 6281-6292. DOI: 10.1038/onc.2016.165.

[10] Yang J, Yuan D, LiJ. miR-186 downregulates protein phos- phatase PPM1B in bladder cancer and mediates G1-S phase transition. Tumour Biol, 2016, 37(4): 4331-4341. DOI: 10.1007/s13277-015-4117-4.

[11] Chang Z, Cui J, Song Y. Long noncoding RNA PVT1 promotes EMT via mediating microRNA-186 targeting of Twist1 in prostate cancer. Gene, 2018 (654): 36-42. DOI: 10.1016/j.gene.2018.02.036.

[12] Lu S, Wang MS, Chen PJ. miRNA-186 inhibits prostate cancer cell proliferation and tumor growth by targeting YY1 and CDK6. Exp Ther Med, 2017, 13 (6): 3309-3314. DOI: 10.3892/etm.2017.4387.

[13] Hua X, Xiao Y, Pan W. miR-186 inhibits cell proliferation of prostate cancer by targeting GOLPH3. Am J Cancer Res, 2016, 6(8): 1650-1660.

[14] Jones DZ, Schmidt ML, Suman S. Micro-RNA-186-5p inhi- bition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells. BMC Cancer, 2018, 18(1): 421. DOI: 10.1186/s12885-018-4258-0.

[15] Jia W, Wu Y, Zhang Q. Identification of four serum microRNAs from a genome-wide serum microRNA expression profile as potential non-invasive biomarkers for endometrioid endo- metrial cancer. Oncol Lett, 2013, 6 (1): 261-267. DOI: 10.3892/ol.2013.1338.

[16] Dong Y, Jin X, Sun Z. MiR-186 inhibited migration of NSCLC via targeting cdc42 and effecting EMT process. Mol Cells, 2017, 40 (3): 195-201. DOI: 10.14348/molcells.2017.2291.

[17] Zhu X, Shen H, Yin X. miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene, 2016, 35(3): 323-332. DOI: 10.1038/onc.2015.84.

[18] Qiu L, Zhang GF, Yu L. Novel oncogenicandchemoresistance- inducing functions of resistin in ovarian cancer cells require miRNAs- mediated induction of epithelial-to-mesenchymal transition. Sci Rep, 2018, 8(1): 12522. DOI: 10.1038/s41598-018-30978-6.

[19] Min C, Eddy SF, Sherr DH. NF-kappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem, 2008, 104(3): 733-744. DOI: 10.1002/jcb. 21695.

[20] Sun KX, Jiao JW, Chen S. MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1. J Ovarian Res, 2015 (8): 80. DOI: 10.1186/s13048-015-0207-6.

[21] Terzuoli E, Donnini S, Finetti F. Linking microsomal prostaglandin E Synthase-1/PGE-2 pathway with miR-15a and-186 expression: Novel mechanism of VEGF modulation in prostate cancer. Oncotarget, 2016, 7 (28): 44350-44364. DOI: 10.18632/oncotarget.10051.

[22] Xiao Q, Wei Z, Li Y. miR186 functions as a tumor suppressor in osteosarcoma cells by suppressing the malignant phenotype and aerobic glycolysis. Oncol Rep, 2018, 39 (6): 2703-2710.DOI: 10.3892/or.2018.6394.